
BACKGROUND: Influenza is a major cause of respiratory illness, contributing substantially to morbidity and mortality in children. Seasonal influenza epidemics were profoundly disrupted by the coronavirus disease 2019 (COVID-19) pandemic. Whether the clinical presentation and disease severity differ according to influenza virus type and subtype remains incompletely understood. This study aimed to describe temporal changes in epidemiology, clinical characteristics, outcomes and healthcare utilization among laboratory-confirmed pediatric influenza cases over 11 seasons and to explore associations between virus type/subtype and clinically important outcomes. METHODS: We conducted a retrospective observational study at a tertiary pediatric hospital, including all laboratory-confirmed influenza cases identified in children presenting with acute respiratory infection between July 2015 and June 2026, and analyzed the distribution of cases and their demographic and clinical characteristics. RESULTS: Influenza was detected in 3105 children (median age, 4 years), the majority of whom were previously healthy (82.4%). Within this cohort, hospitalization was required in 17.9% of cases, with 1.1% requiring intensive care admission, and 22.8% developing complications, including encephalitis and sepsis. Influenza circulation patterns, including the timing of peak activity and the duration of annual epidemics, varied over time. After an 18-month absence of reported cases during the COVID-19 pandemic, the 2021-2022 season was marked by a substantial resurgence, followed by 2 years of atypical year-round circulation before returning to the usual seasonal pattern. Influenza A accounted for 72.3% of cases, with alternating predominance of virus types and subtypes without a consistent epidemiologic pattern. In a restricted type/subtype analysis, influenza A(H1N1) cases had a higher frequency of hospitalization and recorded moderate-to-severe complications, and this association remained statistically significant after multivariable analysis. CONCLUSIONS: Influenza was associated with clinically important illness and healthcare use among children in this hospital-based cohort, most commonly among otherwise healthy children, highlighting the importance of influenza prevention strategies. During and after the COVID-19 pandemic, influenza epidemiology changed markedly, underscoring the need for continued surveillance.
Background: Invasive group A streptococcal (iGAS) infections in children, although rare, are associated with significant morbidity and mortality, and their incidence has risen globally in recent years. Evidence for optimal management in children is limited. These guidelines aim to provide evidence-based recommendations for the management of pediatric iGAS, including antibiotic therapy, adjunctive nonantibiotic therapies and prophylaxis of close contacts.Methods: The ESPID Guidelines Committee convened a multidisciplinary working group. A systematic literature search of pediatric studies published from 2003 to 2023 in PubMed, Embase and the Cochrane Library was performed. Clinical questions with pediatric data were formulated as PICO and assessed using the GRADE approach, with consensus achieved through a modified Delphi process. For clinically important questions lacking sufficient evidence, narrative synthesis with nongraded expert consensus was used. Additional publications until August 2025 contributed qualitatively but were not formally GRADE-graded.Results: Penicillins remain the first-line therapy for iGAS. In severe or toxin-mediated infections (eg, necrotizing fasciitis or streptococcal toxic shock syndrome), adjunctive clindamycin is suggested, with linezolid as an alternative where clindamycin resistance is confirmed or in central nervous system disease. Intravenous immunoglobulin may be considered in life-threatening toxin-mediated disease, whereas evidence for corticosteroids is insufficient. Prophylaxis is recommended for high-risk household contacts (neonates, postpartum women, elderly, immunocompromised, and recent varicella infection) and considered for all contacts in outbreak settings.Conclusions: These ESPID guidelines provide evidence-based recommendations for the management of pediatric iGAS. Given the rarity and limited trial data, most recommendations are weak and supported by low-quality evidence, highlighting the need for high-quality pediatric studies.
Background: Bloodstream infections (BSIs) are associated with a high mortality ratio among critically ill children. BSIs caused by multidrug-resistant (MDR) bacteria are a challenge due to limited therapeutic options. In this multicenter cohort study, factors associated with death of children with bacterial laboratory-confirmed BSI (LC-BSI) admitted to the intensive care unit (ICU) were analyzed, with a focus on MDR bacterial infection and appropriateness of therapy.Methods: A prospective cohort of children <= 18 years of age with LC-BSI, and admitted to 9 ICUs, was conducted from January 1, 2016, to December 31, 2018, in Rio de Janeiro, Brazil. Risk factors of 30- and 7-day death of LC-BSI were identified using multivariable logistic regression analyses.Results: Two hundred thirty-eight LC-BSI episodes occurred in 215 patients; 31.1% were caused by MDR bacteria. Inappropriate initial antibiotic therapy and definitive antibiotic therapy were administered in 50.4% and 8.4% of the episodes, respectively. The 30- and 7-day mortality ratios were 18.5% and 8.8%, respectively. Hematologic disease as primary condition, pediatric risk of mortality score >= 20 on date of LC-BSI, use of vasopressors, ICU-acquired BSI and LC-BSI from hospital B were independently associated with 30-day death. Inappropriate definitive antibiotic therapy; infectious disease, congenital heart disease and hematologic disease as primary conditions; PRISM score >= 20 at the time of LC-BSI; use of/vasopressors and LC-BSI secondary to respiratory tract or intra-abdominal infection were independently associated with 7-day death.Conclusions: Key clinical and healthcare-related factors associated with mortality in LC-BSI were identified.
Background: Echovirus 11 (E11) is a common circulating enterovirus globally and in Malaysia. In recent years, severe neonatal E11 infections have been increasingly reported in Europe and Asia. An increase in severe E11 cases reported in Malaysia highlights significant potential for transmission in postnatal environments in hospitals and the community.Methods: We present clinical and laboratory findings for 5 neonates admitted with laboratory-confirmed E11 infection in Kuala Lumpur, Malaysia, between September 2023 and January 2024. E11 was diagnosed by virus culture or polymerase chain reaction. The E11 VP1 genes were sequenced and compared to other global E11 sequences.Results: Patients were between 2 and 9 days of age. Four cases presented with multiorgan failure with prominent liver dysfunction requiring intensive care, and 2 died. Two had the unusual complication of thrombotic microangiopathy. The fifth patient had uncomplicated meningitis. All cases had E11 viruses of D5 genotype, similar to recently reported global sequences. Two patients with identical virus sequences had been in the same neonatal unit of another hospital, implying a common source. The other 3 were community-acquired cases with related viral sequences. Three cases were admitted from different confinement centers, which are postnatal community care facilities for newborns and mothers.Conclusions: E11 genotype D5 is the main cause of the recent global upsurge of severe neonatal E11 infections. Severe multiorgan disease and hemorrhagic hepatitis syndrome are associated with poor prognosis. E11 transmission in postnatal settings shows the importance of stringent infection control practices, especially in community confinement centers, which are becoming increasingly widespread.